A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
|Articles|March 9, 2020
Contagion Live News Network: Coronavirus Updates for March 9, 2020
Author(s)Contagion® Editorial Staff
Stay on top of coronavirus developments from March 9, 2020.
Advertisement
Welcome to the Contagion Live News Network. I’m Grant Gallagher and this is the COVID-19 update for Monday, March 9, 2020.
The US State Department is advising Americans, particularly those with underlying health conditions, not to travel by cruise ship. The CDC has noted increased risk of infection with COVID-19 in cruise ship environments. Several countries have denied port entry rights to ships and prevented passengers from disembarking.
US health officials continue to monitor passengers from the Grand Princess cruise ship, which was waiting for approval to dock off the coast of California since Thursday. At least 21 people on the ship have been confirmed to have contracted the virus, with only some on board tested. American passengers will be quarantined at various military bases for 14 days. The process of disembarking all 2,421 passengers and sending the crew back to sea is expected to take 2 to 3 days.
Cases continued to be confirmed across the United States over the weekend, bringing the total to 566 confirmed cases across 34 states as of Monday morning. Six states have declared a state of emergency. Twenty two deaths have been reported nationwide.
The coronavirus control efforts continue abroad as well, with Italy quarantining cities in the northern region of the country just days after suspending school activities nationwide. More than 7,300 cases of COVID-19 have been confirmed in Italy.
South Korea has reported around 7500 cases, and on Sunday announced 179 new cases. This is the lowest 1-day total for the country in about 2 weeks. Public health officials remain cautiously optimistic about the slowdown.
For more information on COVID-19, visit ContagionLive.com. To track the spread of coronavirus in the United States and abroad, be sure to use the Contagion Outbreak Monitor.
For the Contagion Live News Network, I’m Grant Gallagher. Thanks for watching.
Advertisement
Related to this article
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Washington State Reports First US Avian Influenza Death of 2026
3
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5